Mallinck­rodt to spin off gener­ics busi­ness; Be­yond­Spring ready to sub­mit ap­proval for lead drug in Chi­na

→ Bare­ly a month af­ter Mallinck­rodt $MNK re­port­ed a key drug fail­ure, the com­pa­ny on Thurs­day said it was spin­ning off its spe­cial­ty gener­ics busi­ness — in­clud­ing Ami­ti­za which it gained from its $1.2 bil­lion ac­qui­si­tion of Su­cam­po — about two years af­ter the UK-based com­pa­ny first said it was seek­ing op­tions for the busi­ness. The gener­ics busi­ness, which ac­count­ed for just over a quar­ter of net sales last year, will re­tain the Mallinck­rodt name and be run by cur­rent CFO Matthew Har­baugh. The spe­cial­ty brand­ed drugs busi­ness, which in­cludes the con­tro­ver­sial drug Ac­thar, will be led by CEO Mark Trudeau, and will al­so be pub­licly list­ed un­der a so-far unan­nounced name.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER